Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for ...
News-Medical.Net on MSN
NIH funds USC team to develop a selective Alzheimer’s drug for APOE4 carriers
Backed by the combined expertise of three USC schools, scientists are developing a new drug aimed at a previously unexplored ...
On 23 September 2025 the TGA made the decision to approve the registration of the lecanemab (LEQEMBI).What is LEQEMBI ...
LEQEMBI is a monoclonal antibody that is administered in a specialised centre via a one-hour intravenous infusion every two weeks and targets the underlying pathology of Alzheimer's disease. 1,2 ...
White-matter hyperintensities disrupt the wiring that carries messages between brain regions, while amyloid gums up the ...
TipRanks on MSN
Biogen, Eisai announces TGA of Australia approved LEQEMBI
Eisai and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA,of Australia has approved the humanized anti ...
1don MSN
Alzheimer's drug Lecanemab approved by Therapeutic Goods Administration for use in Australia
The Therapeutic Goods Administration approves the drug Lecanemab, which can slow down cognitive decline in the early stages ...
A new treatment for early to mild Alzheimer’s disease has been registered with Australia’s pharmaceutical regulator, the ...
Participants were classed as having chronic insomnia if their medical records contained at least two insomnia diagnoses a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback